Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 11.87% is 27% above its 5-year average of 9.34%, around the middle of its 5-year range (5.00%–15.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 12.85% below its 12-month average of 13.62%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.87%.
DEBT TO ASSETS RATIO
11.87%
DEBT TO ASSETS RATIO AVG TTM
13.62%
DEBT TO ASSETS RATIO AVG 3Y
11.19%
DEBT TO ASSETS RATIO AVG 5Y
9.34%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-12.85%
CURRENT VS 3Y AVG
+6.10%
CURRENT VS 5Y AVG
+27.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 597 covered companies
CURRENT VS SECTOR MEDIAN
+11770.04%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$212.94M
Debt to Assets Ratio
11.87%
TTM Avg
13.62%
3Y Avg
11.19%
5Y Avg
9.34%
Market Cap
$215.44M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.14M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$224.84M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$225.88M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$200.14M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $212.94M | 11.87% | 13.62% | 11.19% | 9.34% |
| Compugen Ltd. (CGEN)vs › | $215.11M | 0.02% | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $215.44M | 0.02% | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.14M | 0.00% | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $204.84M | 0.16% | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $224.84M | 0.05% | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.88M | 0.17% | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $200.14M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $228.33M | 0.75% | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $229.55M | 0.10% | N/A | N/A | N/A |
Debt/Assets
11.9%
Debt/Equity
0.16
Current Ratio
5.36
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 11.87% |
| 2026-03-31 | 13.93% |
| 2025-12-31 | 15.00% |
| 2025-09-30 | 13.01% |
| 2025-06-30 | 14.30% |
| 2025-03-31 | 13.28% |
| 2024-12-31 | 12.01% |
| 2024-09-30 | 9.46% |
| 2024-06-30 | 9.21% |
| 2024-03-31 | 8.91% |
| 2023-12-31 | 8.42% |
| 2023-09-30 | 8.13% |
| 2023-06-30 | 7.91% |
| 2023-03-31 | 7.57% |
| 2022-12-31 | 7.22% |
| 2022-09-30 | 6.61% |
| 2022-06-30 | 6.47% |
| 2022-03-31 | 6.29% |
| 2021-12-31 | 6.02% |
| 2021-09-30 | 5.48% |
| 2021-06-30 | 5.00% |
| 2021-03-31 | 6.58% |
| 2020-12-31 | 6.01% |
